Katharina König, Martin Peifer, Jana Fassunke, Michaela A Ihle, Helen Künstlinger, Carina Heydt, Katrin Stamm, Frank Ueckeroth, Claudia Vollbrecht, Marc Bos, Masyar Gardizi, Matthias Scheffler, Lucia Nogova, Frauke Leenders, Kerstin Albus, Lydia Meder, Kerstin Becker, Alexandra Florin, Ursula Rommerscheidt-Fuss, Janine Altmüller, Michael Kloth, Peter Nürnberg, Thomas Henkel, Sven-Ernö Bikár, Martin L Sos, William J Geese, Lewis Strauss, Yon-Dschun Ko, Ulrich Gerigk, Margarete Odenthal, Thomas Zander, Jürgen Wolf, Sabine Merkelbach-Bruse, Reinhard Buettner, Lukas C Heukamp
INTRODUCTION: The Network Genomic Medicine Lung Cancer was set up to rapidly translate scientific advances into early clinical trials of targeted therapies in lung cancer performing molecular analyses of more than 3500 patients annually. Because sequential analysis of the relevant driver mutations on fixated samples is challenging in terms of workload, tissue availability, and cost, we established multiplex parallel sequencing in routine diagnostics. The aim was to analyze all therapeutically relevant mutations in lung cancer samples in a high-throughput fashion while significantly reducing turnaround time and amount of input DNA compared with conventional dideoxy sequencing of single polymerase chain reaction amplicons...
July 2015: Journal of Thoracic Oncology